EyeGate Pharmaceuticals, Inc. Appoints Franz Obermayr as Acting Chief Executive Officer
February 01, 2021 at 06:55 am EST
Share
On January 29, 2021, the Board of Directors of EyeGate Pharmaceuticals, Inc. appointed Franz Obermayr, Ph.D. as Acting Chief Executive Officer of the Company, effective as of February 1, 2021 (the “Effective Date”). Dr. Obermayr has served as EVP Clinical Development of the Company since December 18, 2020, and is a Managing Director of Panoptes Pharma Ges.m.b.H (“Panoptes”). Dr. Obermayr, age 52, served as Co-Founder and CEO of Panoptes since its founding in 2013. Prior to Panoptes, Dr. Obermayr was Head of Clinical Development at Nabriva Therapeutics AG from 2009 to 2013, where he was responsible for all clinical programs, and also served as Program Manager from 2007 to 2009.
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).
KIORA PHARMACEUTICALS, INC. 
